1 Limi A220 3750 nC sero ons cs ves. sve x. 4. piagia, suo CONTAINS NO CB!
refid# vB47GZ3JKrrz9nZZ1LdmOQ4a811 pages
ZVEI pager For a risk-based approach to PFAS - no blanket ban Competent authorities in five European countries earlier this year proposed a wide-ranging restriction on per- and polyfluorinated alkyl substances (PFAS) under the European chemicals regulation REACH.
refid# J3MQxKEE3dy0bzEkwX0ez7gyO3 pages
Estimation of the nb of sequences in PcPc using TFA for synthesis PcPc Data on May-23 nb* % using TFA nb using TFA Dipeptides 82 0% 0 mostly made by liquid phase not using TFA Tripeptides 116 50% 58 Tetrapeptides 113 90% 101 Pentapeptides 120 95% 114 Hexapeptides Heptapeptides 119 95% 79 95% 113 mostly made by SPPS (using TFA) 75 Octapeptides 64 95% 60 Nonapeptides 63 95% 59 Decapeptides 85 95% 80 Oligopeptides (>10AA) 303 10% 30 lower sequences made by SPPS, larger made by biotechno Polypeptides (>100AA) - 0% - mostly made by biotechnology total 1144 total using TFA 690 60% estimated values * these numbers are based on the peptidic "core name" (without prefix and suffix) and may be under evaluated (ex: tripeptide-1; acetyl-tripeptide-1; palmitoyl-tripeptide-1; copper tripeptide-1 are only one sequence in this count!)
refid# Qg7oMdmooJvzKjGpNZeDdwoXk1 page
Dutch Paper and Board industry input on the public consultation on restriction dossier to the European Chemicals Agency (ECHA) on per- and polyfluoroalkyl substances (PFAS).
refid# 6RzGX7B5v0DkJEq9xaGrj2Kk93 pages
refid# BzGpKrx06DK2zEG5g1y5MYJ82 pages
refid# bBR3z4M0qOeYxa9R9L53YEMkO3 pages
Finally, I would like to make sure that the SEA in WP7 will deliver the information needed. 3/2: Apologies I have to change the date of this meeting to the 16th of February.
refid# zd5zjKaG7O8JXav3Be12E3gJm2 pages
refid# MMv0NYvjDg2DQG00oJy1mvwDk1 page
refid# r2YMXn3GJ6wQDJmEpq9zVL3E1 page
-- RREESSTTRRIICCTTEEDD -- HHEEAALLTTHH HHAAZZAARRDD SSUUMMMMAARRIIEESS AANNDD PPRROOPPOOSSEEDD TTEESSTTIINNGG PPRROOGGRRAAMM } FFOORR SSEEVVEERRAALL 33MM FFLLUUOORROOCCHHEEMMIICCAALLSS 33MM FFLLUUOORROOCCHHEEMMIICCAALL TTEECCHHNNIICCAALL AADDVVIISSOORRYY CCOOMMMMIITTTTEEEE SSEEPPTTEEMMBBEERR 66,, 11999944 CCHOEONNNFNFIEIDDPEIENNNTTICIAAOLLUN-- STSUUYBBDJJIEESCCTTTRITTCOTOAACOPPURRROOTTT,EECNCOTT.IIVV2EE7-OOCRRV-DD1EE0RR-28EE8NN6TT2EERREEDD IINN HENNEPIN COUNTY DISTRICT COURT, NO. 27-CV-10-28862 11442211..00000011 Exhibit 1421 33MM_MMNN0022334455223388 : ((33MM RREESST'rRmICCTTEEDD)) HP HUUMMAAR NNSSTO TUUDDIIED ESS-- 3U 3MM PC RODUT CTIOI NWWOO ORRKKEN ERS MMS edeidu cicaar ll Sv urve eilli ancl eTTel essttia inn_ogn PPrroocdg_rre aamm ** BBlloooodd TTeessttiinngg ** CChheemmisisttrryy BBaatttteerryy ** CCoommpplleettee bblloooodd ccoouunntt ((CCBBCC)) ** UUrriinnaallyyssiiss ** SSppiirroommeett~r,y--rreessppiriraattoorryytteessttiinngg ** CChheesstt XX--rraayy ** EEKKGG ** QQuueessttiioonnnnaaiirree : 3 AlAllloowwssffoorr;; ** MMfolorubrobirididnieittyyse((ddriiussmeeaalsseeev))elaassstssoeedssisssmemaeesnnett--stttooatddeeestteerrmmiinneeiifftthheerree iiss aa rreellaatitoinosnhsiphoiofpf fiuodne serum levels to disease states ** HHoororrimmmoomnnueene&&fiiummnmcmtuuinonnee ffuunnccttiioonn--ttooddeetteerrmmiinneeiifftthheerree iiss aann iimmbbaallaannccee iinn hhoorrmmoonnee or immune function **LiLviveerrffuunnccttiioonn tteessttss ((nnoo eeffffeeccttss sseeeenn oovveerr 66-77 yyeeaarrss)) ** RReepprroodduuccttiivvee//ssppeerrmm eeffffeeccttss (( mmoonniittoorreedd tthhrroouugghh ssuurrvveeyyss)) ** IImmmmuunnoollooggiicc eeffffeeccttss -- aabbnnoomrnmalaihttiieess mmoonniittoorreedd aass ppaarrtt ooff bblloooodd ssuurrvveeyy CCHOEONNNFNFIEIDDPEIENNNTTICIAAOLLUN-- STSUUYBBDJJIEESCCTTTRITTCOOTAACOPPURRROOTTT.EECNCOTT.IIVV2EE7-OOCRRV-DD1EE0RR-26EE8NN6TT2EERREEDD IN IN HENNEPIN COUNTY DISTRICT COURT, NO. 27-CV-10-28862 11442211..00000022 33MM_MMNNo022334455223399 . ((33MM RREESSTTRRIICCTTEEDD)) A ANALN YSISA OOFFBBL LLOOOOY DDBBAAS NNKKSSI AAMMPPS LLEES~ PPrroocceedduurree:: ** OObbttaaiinn ssaammpplleess ffrroomm bblloooodd bbanks arroouund tthhee wwoorrlldd ** DDeetteerrmmiinnee -- TToottaall fflluuoorriinnee -- TToottaall oorrggaanniiccfflluuoodrinnee -- CCe8FF1177SSOO;~5" lleevveell =- CCiTFFl1sC5COO2;." lleevveell CCoonnssiiddeerraattiioonnss:: 11..
refid# 5knqLLeypBNorzrrYKqJL69z415 pages
ne DDeeppoonniisseemmiinnaarreett 22001177 PFAS i siiggeevvaannn ffrraa deeppoonniieerr AAssee HHgiissazteeterr,, NNGGII a ALY Na a a 2505 2545 2545.0001 2545.0001 PPFFAASS 1i ssliggeevvaannnn ffrraa ddeeppoonnileerr HHvvaaerr PPFFAASS oogg hhvvoorr bbrruukkeess ddee??
refid# rp0yz3zEG4JpjpjBjeEDJq7Ea28 pages
The presence and Distribution of Perfluorochemicals (PFCs) in Minnesota Fardin Oliaei, Ph.D.
refid# rLBbvxeogbroJv2O5qaKDY5E33 pages
Moving PFAS policy forwards in times of crisis 3M Zwijndrecht Blokkersdijk Port of Antwerp PFOS in top soil 500-1000 g/kg 20 - 100 g/kg 5 - 20 g/kg 3 - 100 g/kg Oosterweel works by Lantis PFAS crisis Role of the PFAS Commissioner PFAS tasks Flanders Coordinate science-policy interface Transparent communication Reporting Region 3M Contact with stakeholders Expert committee - impact of the works Round table stakeholders Information for citizens PFAS communication @vlaanderen.be PFAS IN FLANDERS Overview First interim report Second interim report Third interim report Website PFAS in Flanders Podcast PFAS-pathfinder Town hall meetings Summary of third interim report on the PFAS contamination As commissioned by the Government of Flanders, PFAS commissioner Karl Vrancken presented a third interim report on the PFAS contamination in Flanders in July 2022, the result of the cooperation between and input from numerous experts, each working within their own competence and field of expertise.
refid# mn4Y99j7XGNvYqrLZE2jzEMk17 pages
Meeting Chemours is a different kind of chemistry company, driven by our purpose to create a better world through the power of our chemistry Founded 2015 Employees 6,600 (~5,000 in manufacturing) HQs Delaware Chemours in Europe Manufacturing, Technology and Offices Antwerp (Kallo), Belgium Mechelen, Belgium Brussels, Belgium Dordrecht, the Netherlands Villers-Saint-Paul (Oise), France Antwerp, Belgium Dordrecht Netherlands Meyrin, Switzerland Gijon, Spain Mechelen, Belgium Brussels, Belgium Neu Isenburg Germany Neu Isenburg, Germany +900 employees in Europe across all business units Gijon Spain Oise France Geneva Switzerland EMEA Sales 20% of total Chemours sales (2022) 3 Our activities TITANIUM TECHNOLOGIES ADVANCED PERFORMANCE MATERIALS ` THERMAL & SPECIALIZED SOLUTIONS Our Corporate Responsibility Commitment We invest in responsible chemistry that meets today's needs while providing a better future for all.
refid# NN0JQDeZzoM6VQgLk3axVOYqb18 pages
cnmiEn o------r Namur to 1 IAN 204 Monsieur Fabian Collard Directeur Gnral d'ldelux Drve de I'Arc-en-Ciel, 98 6700 Arlon [ET -------- bit 7Ares stilon province Lieb MonsurlDieter gir oTottoencoutrsrmonn lsantoP.SA ses nds nrc d irmbours sn parenta uaatden1sta esiosonrnsdceoiFemeoirnnifedvoesosvaturonsdeo1 uTBlFan.duSMobdnrdSee.cdedreeoleieIsauns PtAs eoncetrduetrtlnnflsrdopaPrEeRmals Psas iprnotcsi.n te aupregamme enue Sior"en qenosnemanerapsGiratefsultdeasprevents in | evoridcoor, Monsieur Dicergd messtatses elles
refid# VKLQw8vGXpNaYr769J0aN7e9w1 page